Actively Recruiting
Phase 2 Study of BrECADD Therapy for Adults Aged 18 to 60 with Stage 2B-IV Classical Hodgkin Lymphoma
Led by University of Miami · Updated on 2025-11-03
48
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the effectiveness and tolerability of a treatment regimen called BrECADD, which includes Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone, in patients with Stage 2 B-IV Hodgkin Lymphoma. The study also explores the use of circulating tumor DNA ctDNA as a biomarker to monitor minimal residual disease and treatment response depth. This is a Phase 2 clinical trial supported by the University of Miami. Participants will receive the BrECADD regimen following recommended doses from United States Package Inserts. Brentuximab Vedotin is given intravenously on Day 1 of each 21-day cycle for up to 4 cycles. Etoposide is administered intravenously on Days 1-3, Cyclophosphamide and Doxorubicin intravenously on Day 1, Dacarbazine intravenously on Days 2-3, and Dexamethasone is self-administered orally on Days 1-4 of each cycle. Total participation lasts up to 24 months. During the study, participants will undergo assessments including scans and laboratory tests to monitor tumor response and side effects. Researchers will measure progression-free survival at 12 months as the primary outcome and evaluate safety through the number of adverse events and treatment toxicity up to 40 months. Participants will provide informed consent and be monitored regularly throughout the trial period.
CONDITIONS
Brief Title
BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma
Research Team
M
Michele Stanchina, DO
C
Craig Moskowitz, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
